Form 4: Pediatrix Director Guy Sansone Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Guy P. Sansone was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.
Summary
- Director Guy P. Sansone acquired 7,196 shares of common stock in Pediatrix Medical Group, Inc. (MD).
- The shares were granted as restricted stock under the company's Amended and Restated 2008 Incentive Compensation Plan.
- The transaction occurred on May 7, 2026, at a price of $0 per share as part of an annual equity compensation package.
- Following this transaction, Mr. Sansone's total beneficial ownership in the company increased to 86,944 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- The equity grant aligns the interests of the director with those of shareholders through long-term stock ownership.
- The shares are subject to a one-year vesting period, encouraging retention and commitment to the company's performance.
Negatives
- None identified; this is a standard compensatory equity grant for a board member.
Risks
- The value of the granted shares is subject to market volatility and the future performance of Pediatrix Medical Group, Inc.
Future Outlook
The restricted shares are scheduled to vest on May 7, 2027, contingent upon continued service.
Industry Context
StockSavvy.ai notes that annual equity grants to board members are a standard corporate governance practice in the healthcare services sector to ensure alignment between leadership and shareholder interests.
Comparison to Industry Standards
- The grant of restricted stock units (RSUs) as part of annual director compensation is consistent with standard practices for mid-cap healthcare companies.
- The one-year vesting schedule is typical for non-employee director equity awards in the U.S. public market.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Guy P. Sansone authorized Mary Ann E. Moore and Tara McManus to file SEC documents on his behalf. | 2025-10-28 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Shareholders: Minimal impact; reflects standard director compensation.
Next Steps
- Vesting of the 7,196 restricted shares on May 7, 2027.
Key Dates
| Date | Description |
|---|---|
| 2025-10-28 | Date of execution for the Power of Attorney. |
| 2026-05-07 | Date of the equity grant transaction. |
| 2027-05-07 | Vesting date for the restricted shares. |
| 2026-05-11 | Date of filing for the Form 4. |
Keywords
Pediatrix Medical Group, MD, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.